Apoptotic Processes in Megakaryocytes and Platelets

Seminars in Hematology

Volumn 47, Issue 3, 2010, Pages 227-234

  White, Michael J ^a,b   Kile, Benjamin T ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BCL2 RELATED PROTEIN A1; BIM PROTEIN; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CISPLATIN; CYTARABINE; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE B; PROTEIN MCL 1; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; ENZYME ACTIVATION; GENE MUTATION; HEMOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEGAKARYOCYTE; MEGAKARYOPOIESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOSIS;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOOD PLATELETS; HUMANS; MEGAKARYOCYTES;

EID: 77953891657     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.03.006     Document Type: Article

References (75)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Dieker J.W., van der Vlag J., Berden J.H. Deranged removal of apoptotic cells: its role in the genesis of lupus. Nephrol Dial Transplant 2004, 19:282-285.
3. Broughton B.R., Reutens D.C., Sobey C.G. Apoptotic mechanisms after cerebral ischemia. Stroke 2009, 40:e331-e339.
4. Lee Y., Gustafsson A.B. Role of apoptosis in cardiovascular disease. Apoptosis 2009, 14:536-548.
5. Thomas H.E., McKenzie M.D., Angstetra E., Campbell P.D., Kay T.W. Beta cell apoptosis in diabetes. Apoptosis 2009, 14:1389-1404.
6. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008, 9:47-59.
7. Lindsten T., Ross A.J., King A., et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol Cell 2000, 6:1389-1399.
8. Wei M.C., Zong W.X., Cheng E.H., et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292727-30.
9. Dewson G., Kratina T., Sim H.W., et al. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. Molecular cell 2008, 30(3):369-380.
10. Newmeyer D.D., Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003, 112:481-490.
11. Hakem R., Hakem A., Duncan G.S., et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998, 94:339-352.
12. Li P.S., Nijhawan D., Budihardjo I., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
13. Gavathiotis E., Suzuki M., Davis M.L., et al. BAX activation is initiated at a novel interaction site. Nature 2008, 455:1076-1081.
14. Willis S.N., Fletcher J.I., Kaufmann T., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007, 315:856-859.
15. Tartaglia L.A., Ayres T.M., Wong G.H., Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993, 74:845-853.
16. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85:803-815.
17. Muzio M., Chinnaiyan A.M., Kischkel F.C., et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85:817-827.
18. Aggarwal S., Gupta S. Increased activity of caspase 3 and caspase 8 in anti-Fas-induced apoptosis in lymphocytes from ageing humans. Clin Exp Immunol 1999, 117:285-290.
19. Gross A., Yin X.M., Wang K., et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999, 274:1156-1163.
20. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
21. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
22. Wei M.C., Lindsten T., Mootha V.K., et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000, 14:2060-2071.
23. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol 2009, 46(Suppl 2):S26-S32.
24. Herr I., Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 2001, 98:2603-2614.
25. Ballem P.J., Segal G.M., Stratton J.R., Gernsheimer T., Adamson J.W., Slichter S.J. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987, 80:33-40.
26. Chang M., Nakagawa P.A., Williams S.A., et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003, 102:887-895.
27. Houwerzijl E.J., Blom N.R., van der Want J.J., et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004, 103:500-506.
28. McMillan R., Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol 2005, 81:94-99.
29. Zauli G., Catani L., Gibellini D., et al. Impaired survival of bone marrow GPIIb/IIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia. Br J Haematol 1996, 92:711-717.
30. Zucker-Franklin D., Termin C.S., Cooper M.C. Structural changes in the megakaryocytes of patients infected with the human immune deficiency virus (HIV-1). Am J Pathol 1989, 134:1295-1303.
31. Zeuner A., Signore M., Martinetti D., Bartucci M., Peschle C., De Maria R. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res 2007, 67:4767-4773.
32. Sanz C., Benet I., Richard C., et al. Antiapoptotic protein Bcl-x(L) is up-regulated during megakaryocytic differentiation of CD34(+) progenitors but is absent from senescent megakaryocytes. Exp Hematol 2001, 29:728-735.
33. Kozuma Y., Kojima H., Yuki S., Suzuki H., Nagasawa T. Continuous expression of Bcl-xL protein during megakaryopoiesis is post-translationally regulated by thrombopoietin-mediated Akt activation, which prevents the cleavage of Bcl-xL. J Thromb Haemost 2007, 5:1274-1282.
34. Nakao T., Geddis A.E., Fox N.E., Kaushansky K. PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27(Kip1). Cell Cycle 2008, 7:257-266.
35. Wagner K.U., Claudio E., Rucker E.B., et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 2000, 127:4949-4958.
36. Hikita H., Takehara T., Shimizu S., et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology 2009, 50:1217-1226.
37. Oltersdorf T., Elmore S., Shoemaker A., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
38. Tse C., Shoemaker A.R., Adickes J., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008, 68:3421-3428.
39. Zauli G., Vitale M., Falcieri E., et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood 1997, 90:2234-2243.
40. Falcieri E., Bassini A., Pierpaoli S., et al. Ultrastructural characterization of maturation, platelet release, and senescence of human cultured megakaryocytes. Anat Rec 2000, 258:90-99.
41. Bouillet P., Metcalf D., Huang D.C., et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999, 286:1735-1738.
42. Ogilvy S., Metcalf D., Print C.G., Bath M.L., Harris A.W., Adams J.M. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A 1999, 96:14943-14948.
43. Kaluzhny Y., Yu G., Sun S., et al. BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood 2002, 100:1670-1678.
44. De Botton S., Sabri S., Daugas E., et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002, 100:1310-1317.
45. Clarke M.C., Savill J., Jones D.B., Noble B.S., Brown S.B. Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol 2003, 160:577-587.
46. Chauvier D., Ankri S., Charriaut-Marlangue C., Casimir R., Jacotot E. Broad-spectrum caspase inhibitors: from myth to reality?. Cell Death Differ 2007, 14:387-391.
47. Schotte P., Declercq W., Van Huffel S., Vandenabeele P., Beyaert R. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett 1999, 442:117-121.
48. Kozuma Y., Yuki S., Ninomiya H., Nagasawa T., Kojima H. Caspase activation is involved in early megakaryocyte differentiation but not in platelet production from megakaryocytes. Leukemia 2009, 23:1080-1086.
49. Morison I.M., Borde E.M., Cheesman E.J., et al. A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat Genet 2008, 40:387-389.
50. Leeksma C.H., Cohen J.A. Determination of the life of human blood platelets using labelled diisopropylfluorophosphanate. Nature 1955, 175:552-553.
51. Ault K.A., Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995, 23:996-1001.
52. Vanags D.M., Orrenius S., Aguilar-Santelises M. Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. Br J Haematol 1997, 99:824-831.
53. Mason K.D., Carpinelli M.R., Fletcher J.I., et al. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
54. Zhang H., Nimmer P.M., Tahir S.K., et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007, 14:943-951.
55. Catani M.V., Gasperi V., Evangelista D., Finazzi Agrò A., Avigliano L., Maccarrone M. Anandamide extends platelets survival through CB(1)-dependent Akt signaling. Cell Mol Life Sci 2009, 67:601-610.
56. Bertino A.M., Qi X.Q., Li J., Xia Y., Kuter D.J. Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion 2003, 43:857-866.
57. Brown S.B., Clarke M.C., Magowan L., Sanderson H., Savill J. Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis. A caspase-independent cell clearance program. J Biol Chem 2000, 275:5987-5996.
58. Leytin V., Freedman J. Platelet apoptosis in stored platelet concentrates and other models. Transfus Apher Sci 2003, 28:285-295.
59. Li J., Xia Y., Bertino A.M., Coburn J.P., Kuter D.J. The mechanism of apoptosis in human platelets during storage. Transfusion 2000, 40:1320-1329.
60. Perrotta P.L., Perrotta C.L., Snyder E.L. Apoptotic activity in stored human platelets. Transfusion 2003, 43:526-535.
61. Plenchette S., Moutet M., Benguella M., et al. Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. Leukemia 2001, 15:1572-1581.
62. Shcherbina A., Remold-O'Donnell E. Role of caspase in a subset of human platelet activation responses. Blood 1999, 93:4222-4231.
63. Wolf B.B., Goldstein J.C., Stennicke H.R., et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood 1999, 94:1683-1692.
64. Schoenwaelder S.M., Yuan Y., Josefsson E.C., et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009, 114:663-666.
65. Lakhani S.A., Masud A., Kuida K., et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006, 311:847-851.
66. Ekert P.G., Read S.H., Silke J., et al. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J Cell Biol 2004, 165:835-842.
67. Marsden V.S., Kaufmann T., O'Reilly L.A., Adams J.M., Strasser A. Apaf-1 and caspase-9 are required for cytokine withdrawal-induced apoptosis of mast cells but dispensable for their functional and clonogenic death. Blood 2006, 107:1872-1877.
68. Bergmeier W., Burger P.C., Piffath C.L., et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood 2003, 102:4229-4235.
69. Bevers E.M., Comfurius P., Zwaal R.F. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta 1983, 736:57-66.
70. Leytin V., Allen D.J., Mykhaylov S., Lyubimov E., Freedman J. Thrombin-triggered platelet apoptosis. J Thromb Haemost 2006, 4:2656-2663.
71. Jobe S.M., Wilson K.M., Leo L., et al. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood 2008, 111:1257-1265.
72. Arachiche A., Kerbiriou-Nabias D., Garcin I., Letellier T., Dachary-Prigent J. Rapid procoagulant phosphatidylserine exposure relies on high cytosolic calcium rather than on mitochondrial depolarization. Arterioscler Thromb Vasc Biol 2009, 29:1883-1889.
73. Orrenius S., Zhivotovsky B., Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 2003, 4:552-565.
74. Zhang J., Randall M.S., Loyd M.R., et al. Mitochondrial clearance is regulated by Atg7-dependent and -independent mechanisms during reticulocyte maturation. Blood 2009, 114:157-164.
75. Houwerzijl E.J., Blom N.R., van der Want J.J., Vellenga E., de Wolf J.T. Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia 2006, 20:1937-1942.